Mechanism breakdowns, research summaries, and catalog notes. Educational content for the research community — not medical advice.
Comparing recombinant human growth hormone with IGF-1 LR3 on mechanism, receptor architecture, GH pulse pattern, and the state of the published research record.
Read article → September 16, 2026Residual solvents from peptide synthesis are invisible to HPLC and mass spec, need a gas chromatograph, and reveal which side reactions a process ran.
Read article → September 15, 2026How fragment peptides like HGH Fragment 176-191, kisspeptin-10, Ara-290 and KPV relate to their parent proteins, and why the parent's evidence rarely transfers.
Read article → September 14, 2026KPV is what remains of alpha-MSH after the receptor-binding motif is removed. A look at its PepT1 uptake route, its divergence from its parent, and its empty human file.
Read article → September 13, 2026Why a published plasma peptide concentration belongs to the assay that produced it — immunoassay epitopes, LC-MS/MS matrix effects, preanalytics, and IGF-1 platform discordance.
Read article → September 12, 2026A mechanism explainer on the circadian system: the SCN pacemaker, melanopsin input, AANAT output, MT1/MT2 receptors, and why the phase response curve makes timing the variable.
Read article → September 11, 2026A roundup of published analytical and pharmacovigilance studies on unregulated peptide products — content, purity, endotoxin and identity measured separately.
Read article → September 10, 2026Two thymus-derived research compounds compared on structure, naming history and evidence: a defined 28-residue peptide versus a polypeptide extract.
Read article → September 9, 2026Why D-amino acids are invisible to routine peptide testing, how chiral purity is actually measured, and which research compounds the question applies to.
Read article → September 8, 2026A category primer on research peptide blends: how the five co-formulations differ, why the ratio is the product, and what one purity number cannot describe.
Read article → September 7, 2026Ara-290 (cibinetide) is one of few research peptides with posted Phase 2 results. Reading the registry table beside the published paper changes what it shows.
Read article → September 6, 2026A foundations guide to checking peptide citations: what a PMID or DOI actually proves, how to check for retractions, and why a real paper can still be cited wrongly.
Read article → September 5, 2026A mechanism explainer on the incretin axis: L cells and K cells, glucose-dependent amplification, DPP-4 at the source, the neural arm, and central GLP-1.
Read article → September 4, 2026A 2025-2026 roundup on Epithalon and Thymalin: the first independent telomerase replication, a correction, a paper that only looks independent, and an empty registry.
Read article → September 3, 2026Two multi-agonist peptides both add glucagon receptor activity to a GLP-1 backbone. Comparing mechanism, trial estimands, and documentation.
Read article → September 2, 2026Glass type, stopper moisture, leachable metals and integrity testing. Why the container holding a research peptide is a variable, not neutral packaging.
Read article → September 1, 2026How the sexual-health peptide category was assembled from an unexpected observation in a tanning study, and why its members answer three unrelated research questions.
Read article → August 31, 2026GHK-Cu deep dive: the 1973 origin, copper as an exchangeable equilibrium rather than a fixed part of the molecule, the real source of the gene-expression claim, and 2026 literature.
Read article → August 30, 2026A foundations guide to net charge, isoelectric point, hydrophobicity and adsorption — and why a peptide's measured behaviour depends on the solution it is in.
Read article → August 29, 2026A mechanism explainer on peptide cell entry: transporters, endocytosis, the endosomal escape bottleneck, direct translocation, and two classic artifacts.
Read article → August 28, 20262026 research on NAD+ precursors, NNMT inhibition and AICAR: target engagement without outcomes, the 2PY/4PY disposal problem, and an empty registry.
Read article → August 27, 2026Ipamorelin and hexarelin both act at GHS-R1a, but differ in hormonal spillover, a second non-GHS target, and the kind of human evidence each one has.
Read article → August 26, 2026Intact mass confirms composition, not order. How tandem MS builds a sequence ladder, why peptide mapping is a protein test, and what stays invisible.
Read article → August 24, 2026MGF was originally the name of an mRNA splice variant, not a molecule. What that means for the 24-mer in the vial, its disputed mechanism, and PEGylation.
Read article → August 23, 2026A foundations guide to the peptide-protein boundary: the textbook convention, the structural line, and the FDA's 40-amino-acid rule — and why each matters.
Read article → August 21, 2026MOTS-c and humanin research in 2025-2026: CK2 identified as a direct binding partner, two new muscle studies, and why the cited human trial is not real.
Read article → August 20, 2026Sermorelin truncates GHRH; tesamorelin caps it. Comparing two GHRH-receptor analogs on structure, the label half-life record, and two very different evidence files.
Read article → August 19, 2026A certificate of analysis describes a lot at a moment in time, not the vial in your hand. How lots, sampling, and retest dates work in peptide documentation.
Read article → August 18, 2026On the hormonal shelf the compound is the signal itself, inside a feedback loop. The same molecule at one receptor can drive an axis up or shut it down.
Read article → August 17, 2026Dermorphin's D-alanine, its mu-opioid pharmacology, a forgotten 1985 randomized trial, and the mitochondrial drug that descended from its analog chemistry.
Read article → August 16, 2026One-letter codes, N-to-C direction, termini, D-amino acids, cyclization and fragment numbering — how to read the sequence line on a research peptide spec sheet.
Read article → August 15, 2026DPP-4, neprilysin, aminopeptidases and renal filtration explain why most peptides last minutes — and why catalog compounds carry Aib, D-residues and amide caps.
Read article → August 14, 2026A ClinicalTrials.gov number looks like proof. This roundup checks 2026 peptide registrations, corrects one we cited, and shows how to verify a record.
Read article → August 13, 2026A mechanism and literature comparison of BPC-157 and TB-500: what each molecule really is, why neither has a receptor, and how their human files differ.
Read article → August 12, 2026The purity percentage on a peptide COA is a transcription. The chromatogram and mass spectrum behind it are the primary data. Here is how to read both.
Read article → August 11, 2026Every other peptide category is sorted by receptor. The cosmetic class is sorted by whether the molecule crosses the stratum corneum at all.
Read article → August 10, 2026IGF-1 LR3's modifications were engineered to defeat IGF binding proteins. What that does in serum-free cell culture, and why its half-life claim is backwards.
Read article → August 9, 2026A foundations guide to the evidence ladder for research peptides: what in vitro, animal, and human trial data can and cannot establish, and how to read each rung.
Read article → August 7, 2026The 2026 oxytocin alcohol trial, a SOARS-B reanalysis, melatonin's heart-failure signal and its NHANES rebuttal, and where DSIP research actually went.
Read article → August 6, 2026A mechanism-first comparison of HCG and HMG: shared alpha subunit, the hCG beta CTP tail, and why published analyses find hMG's LH activity is largely hCG.
Read article → August 5, 2026HPLC purity answers how clean. Net peptide content answers how much. Here is how amino acid analysis, UV spectrophotometry, and Karl Fischer actually measure it.
Read article → August 4, 2026The immune shelf isn't one mechanism or even one direction. A primer sorting thymic, host-defense and resolution peptides by what they actually do.
Read article → August 3, 2026FOXO4-DRI targets the FOXO4–p53 interaction inside senescent cells. Its mechanism, D-retro-inverso design, replication record, and empty human trial file.
Read article → August 2, 2026What agonist, partial agonist, affinity, potency, selectivity and biased agonism actually mean — the pharmacodynamics vocabulary behind peptide research literature.
Read article → August 1, 2026How syntaxin, SNAP-25 and VAMP zipper membranes together to release neurotransmitters and hormones — and where the peptide-mimetic evidence actually gets thin.
Read article → July 31, 2026Recent peer-reviewed findings on the GH axis: cryo-EM structures of the ghrelin receptor, anamorelin real-world data, oral LUM-201 in Phase 3, and tesamorelin.
Read article → July 30, 2026Selank and Semax share a Pro-Gly-Pro tail and a design lineage, but their N-terminal fragments come from unrelated parent molecules. A mechanism comparison.
Read article → July 29, 2026Chemical synthesis, recombinant expression, or extraction from urine — the manufacturing route sets the impurity fingerprint and which COA tests can catch it.
Read article → July 28, 2026The metabolic shelf isn't one mechanism. A primer sorting incretins, AMPK activators, NNMT inhibition and fat-cell-directed compounds by where each acts.
Read article → July 27, 2026Adipotide isn't a signaling peptide — it's a homing address fused to a cytotoxic warhead. Prohibitin targeting, the primate data, and the real trial record.
Read article → July 20, 2026SS-31 (elamipretide) is a cardiolipin-targeting mitochondrial tetrapeptide. Inside its mechanism, its 2025 Barth syndrome approval, and its mixed trial record.
Read article → July 19, 2026A foundations guide to peptide blends and stacks: why researchers combine compounds, the mechanistic rationale, the evidence caveats, and the QC trade-offs.
Read article → July 18, 2026A research-focused explainer of the angiogenesis pathway—how hypoxia, HIF-1α, VEGF and VEGFR-2 grow new blood vessels, and where peptides intersect it.
Read article → July 17, 2026A research roundup on kisspeptin and melanocortin peptides: recent HSDD brain-processing trials, IVF and reproductive-hormone studies, and 2026 readouts.
Read article → July 16, 2026A mechanism comparison of semaglutide and tirzepatide: single GLP-1 agonist vs dual GIP/GLP-1 twincretin, biased agonism, PK, and head-to-head trial data.
Read article → July 15, 2026HPLC purity and mass spec cannot see endotoxin. How the LAL test, recombinant Factor C, and EU/mg measure the microbial axis of research peptide quality.
Read article → July 14, 2026A category primer on growth-hormone peptides: how GHRH analogs, ghrelin-mimetic GHRPs, recombinant GH, and IGF-1 mediators act at different points of one axis.
Read article → July 13, 2026AOD-9604 is a modified hGH C-terminal fragment engineered to isolate fat metabolism from growth effects. Unlike most of the shelf, it has a real Phase IIb trial record.
Read article → July 12, 2026A foundations guide to lyophilization: how freeze-drying removes water from research peptides, what the cake in the vial tells you, and why the powder lasts.
Read article → July 11, 2026How the melanocortin system turns a single POMC precursor into five Gs-coupled receptors that govern pigment, adrenal steroids, appetite, and sexual signaling.
Read article → July 10, 2026Recent peer-reviewed readouts on immune-modulating peptides—Thymosin Alpha-1's negative BMJ sepsis trial, LL-37 reviews, VIP and Ara-290 in sarcoidosis.
Read article → July 8, 2026Synthetic peptides ship as a salt, and the counterion is rarely on the label. Here is why TFA vs acetate matters for research, and how it shows on a COA.
Read article → July 7, 2026A research primer on the longevity peptide category—Epithalon, NAD+, SS-31, FOXO4-DRI and Thymalin—and how each targets a distinct hallmark of aging.
Read article → July 5, 2026A plain-language primer on peptide pharmacokinetics—half-life, Tmax, clearance, and bioavailability—and why these numbers shape research design.
Read article → July 4, 2026A clear mechanism explainer of the hypothalamic-pituitary-gonadal (HPG) axis: GnRH pulsatility, the KNDy pulse generator, feedback loops, and where research peptides map on.
Read article → July 3, 2026A research roundup on BPC-157, TB-500 and GHK-Cu: the first human safety data, a 2026 review, and the widening gap between preclinical volume and clinical evidence.
Read article → July 2, 2026CJC-1295 DAC vs No-DAC compared on mechanism, half-life, and GH pulsatility. What the Drug Affinity Complex does and why it splits one peptide into two research tools.
Read article → July 1, 2026A look at the chemistry behind peptide instability — oxidation, deamidation, aggregation — and why lyophilized form, temperature, and light exposure matter for research integrity.
Read article → June 30, 2026A neutral primer on the cognitive-mood research peptide class—Selank, Semax, DSIP, melatonin and oxytocin—and how their mechanisms diverge under one label.
Read article → June 29, 2026A research deep-dive on Epithalon (Ala-Glu-Asp-Gly): its origin in pineal peptide research, proposed telomerase mechanism, melatonin rhythm work, and the state of the evidence.
Read article → June 28, 2026Learn to read peptide names like a researcher: suffixes, fragment numbers, DAC vs No-DAC, LR3, salt forms, and what the labels on a vial actually mean.
Read article → June 27, 2026A clear mechanism explainer of the growth-hormone secretagogue axis — GHRH and ghrelin receptors, the somatostatin brake, pulsatility, and IGF-1 feedback.
Read article → June 26, 2026A neutral roundup of recent peer-reviewed incretin and amylin peptide trial data — retatrutide, survodutide, CagriSema, and emerging amylin analogs.
Read article → June 25, 2026Melanotan 1 and Melanotan 2 are both melanocortin analogs, but receptor selectivity sets them apart. A neutral research comparison of mechanism, structure, and PK.
Read article → June 24, 2026Purity and identity are two different questions. Here's what HPLC, mass spectrometry, and the rest of a peptide analytical panel each actually verify.
Read article → June 23, 2026A research primer on the healing & recovery peptide category — BPC-157, TB-500, GHK-Cu, KPV, LL-37, VIP and more — and how their mechanisms diverge.
Read article → June 22, 2026A research deep-dive into MOTS-c, the 16-amino-acid mitochondrial peptide that activates AMPK, signals to the nucleus, and mimics exercise in metabolic models.
Read article → June 22, 2026A COA is only as good as your ability to read it. Here is what HPLC purity, mass spec confirmation, and net peptide content actually tell you about a research compound.
Read article →